Flot.bio x Philip Hemme

We’re in Hannover 🇩🇪 with the founder and CEO of Cardior, Claudia Ulbrich We talked about Cardior’s recent €1B exit to Novo Nordisk. We also talk about miRNA and Cardiovascular, and why she earned the funny nickname “Frau Biotech”. 💎 ABOUT THE SPEAKER Claudia has been founding biotechs since the ’90s. She founded her first biotech company, LipoNova AG in 1998 and went on to co-found many more, including Cardior Pharmaceuticals. During her time she has launched and brought public a cancer vaccine company, helped see through a multi-million dollar deal of over €20M, and much more. 🔗 LINKS MENTIONED - Novo Nordisk to acquire Cardior Pharmaceuticals and strengthen pipeline in cardiovascular disease: https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=167038 📜 TRANSCRIPT Read the full transcript here: 🫶 FOLLOW US - Newsletter: http://eepurl.com/h_fnmH - LinkedIn: https://www.linkedin.com/company/flot-bio/ - X: https://x.com/FlotBio 🎙️ ABOUT FLOT.BIO Flot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 15k monthly views. Free. ⭐️ SPONSORSHIP Ready to amplify your brand to influential leaders in biotech and biopharma? Contact nick@flot.bio and unlock sponsorship opportunities in our podcasts! 🙏 LIKE/FOLLOW/REVIEW Did you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below. ⏰ TIMESTAMPS [00:00:00] Intro [00:01:47] Novo Nordisk deal [00:10:19] Results from heart disease phase1 [00:19:55] MicroRNA [00:26:42] The history of Cardior [00:41:49] Working with Centerview [00:45:17] Frau Biotech [00:53:57] Thanks for listening

We’re super privileged to chat online with Bahija Jallal, the CEO of Immunocore. Immunocore is the largest biotech in the UK and the 5th largest in Europe with a market cap of just over 3 billion dollars. We talk about how Immunocore has helped thousands of cancer patients and has become a commercial biotech. We also talk about why she thinks gender and race diversity are a business case and how AI is changing protein and biologics engineering. 💎 ABOUT THE SPEAKER I’ve “known” Bahija for over 10 years, after reading her profile in a student pharma magazine when I was studying bioengineering in France. At that time, she was head of MedImmune and SVP R&D at AstraZeneca. Now as the CEO of Immunocore, with their pioneering T cell receptor platform, she has helped to bring incredible treatments for cancer patients to market. 🔗 LINKS MENTIONED - Bahija on the Breakthrough Labs podcast - https://open.spotify.com/episode/2X4xedUdJid9GeioRSkCrP?si=39d8c7511aab443f - Immatics builds on its PRAME Success (and competes with Immunocore) - [OncologyPipeline.com](https://www.oncologypipeline.com/apexonco/immatics-builds-its-prame-success) 📜 TRANSCRIPT Read the full transcript here: 🫶 FOLLOW US - Newsletter: http://eepurl.com/h_fnmH - LinkedIn: https://www.linkedin.com/company/flot-bio/ - X (Twitter): https://x.com/FlotBio 🎙️ ABOUT FLOT.BIO Flot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 15k monthly views. Free. ⭐️ SPONSORSHIP Ready to amplify your brand to influential leaders in biotech and biopharma? Contact nick@flot.bio and unlock sponsorship opportunities in our podcasts! 🙏 LIKE/FOLLOW/REVIEW Did you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below. ⏰ TIMESTAMPS [00:00:00] Intro [00:00:34] Welcome [00:01:46] Immunocore’s life-changing cancer drug [00:07:40] Commercializing Immunocore [00:13:46] Explaining the TCR technology [00:20:40] Targeting tumors with PRAME [00:23:26] Immunocore now and then [00:35:37] Why Bahija chose Immunocore [00:40:22] Top lessons from Bahija Jallal [00:45:48] How is risk appetite connected to innovation? [00:49:10] Diversity in biotech [01:00:59] Biological innovation [01:05:49] AI in protein engineering optimization [01:14:42] Thanks for listening

We’re in Brussels with Edwin Moses, the former CEO of one of the most successful platform companies in Europe, Ablynx, now part of Sanofi. We talk about how he feels 5 years after the exit from Ablynx and his lessons. We also talk about the parallels between industrial biotech, AI bio and cell therapy, and how a chairman can help CEOs grow. 💎 ABOUT THE SPEAKER Edwin Moses is Chairman of Achilles Thx (cell therapy for solid tumors), Avantium (bioplastics) and LabGenius (AI biotech). He is the former CEO of one of the most successful platform companies in Europe, Ablynx, now part of Sanofi. I interviewed him back in 2018 when he sold the company. 📜 TRANSCRIPT Read the full transcript here: https://flot.bio/episode/edwin-moses-biotech-platforms/ 🔗 LINKS MENTIONED https://www.sanofi.com/en/media-room/press-releases/2018/2018-01-29-07-19-03-1313306 Edwin Moses on stage in 2018 - https://www.youtube.com/watch?v=nWkd99rxVhc&t=802s&pp=ygUVZWR3aW4gbW9zZXMgbGFiaW90ZWNo 🫶 FOLLOW US - Newsletter: http://eepurl.com/h_fnmH - LinkedIn: https://www.linkedin.com/company/flot-bio/ - X (Twitter): https://x.com/FlotBio 🎙️ ABOUT FLOT.BIO Flot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 15k monthly views. Free. ⭐️ SPONSORSHIP Ready to amplify your brand to influential leaders in biotech and biopharma? Contact nick@flot.bio and unlock sponsorship opportunities in our podcasts! 🙏 LIKE/FOLLOW/REVIEW Did you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below. ⏰ TIMESTAMPS

We’re in Copenhagen with Jens Nielsen, the CEO of BioInnovation Institute. We will talk about what works best to translate academic research in bio into innovation for humanity, especially how everything is connected. We also talk about how BII is solving some of the main challenges scientist entrepreneurs face and the drawbacks of Novo financing most of Denmark’s biotech ecosystem. 💎 ABOUT THE SPEAKER Jens Nielsen is one of the best in this space in Europe. Not only is he the CEO of BII, he’s also a professor of systems biology at Chalmers University of Technology in Sweden, and is the most cited researcher in the field of metabolic engineering as well as industrial biotechnology. He’s the founder of the International Metabolic Engineering Society and has also founded many biotechs. 📜 TRANSCRIPT Read the full transcript here: https://flot.bio/episode/jens-nielsen-translation-of-life-science-research/ 🫶 FOLLOW US - Newsletter: http://eepurl.com/h_fnmH - LinkedIn: https://www.linkedin.com/company/flot-bio/ - X (Twitter): https://x.com/FlotBio 🎙️ ABOUT FLOT.BIO Flot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 10k monthly views. Free. ⭐️ SPONSORSHIP Ready to amplify your brand to influential leaders in biotech and biopharma? Contact nick@flot.bio and unlock sponsorship opportunities in our podcasts! 🙏 LIKE/FOLLOW/REVIEW Did you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below. ⏰ TIMESTAMPS [00:00:00] Intro [00:00:29] Welcome [00:01:43] Translation of science [00:08:48] Being flexible is key [00:11:58] When to stop being flexible [00:19:34] Listen to your gut [00:22:38] The importance of network [00:28:05] Entrepreneurial mindset recipe [00:31:08] Role models [00:32:38] Interaction with industry [00:43:07] Results of BII [00:54:14] How to be cost-effective in helping startups [00:57:56] Novo Nordisk [01:11:07] Closing the lab [01:17:46] Thanks for listening

We’re in Amsterdam with Sander van Deventer, the CEO of VectorY. We will talk about VectorY and what’s missing in gene therapy. 💎 ABOUT THE SPEAKER Sander has an impressive track record, being a professor, operational biotech founder and a VC. In 1998, he co-founded uniQure, which brought the first gene therapy to the market. He also co-founded the leading VC Forbion as well as Dezima. He is now building a new venture VectorY, again in gene therapy. I interviewed him in 2017 back at Labiotech so it’s great to catch up with him again. 📜 TRANSCRIPT Read the full transcript here: https://flot.bio/episode/sander-van-deventer-gene-therapy/ 🫶 FOLLOW US - Newsletter: http://eepurl.com/h_fnmH - LinkedIn: https://www.linkedin.com/company/flot-bio/ - X (Twitter): https://x.com/FlotBio 🎙️ ABOUT FLOT.BIO Flot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 10k monthly views. Free. ⭐️ SPONSORSHIP Ready to amplify your brand to influential leaders in biotech and biopharma? Contact nick@flot.bio and unlock sponsorship opportunities in our podcasts! 🙏 LIKE/FOLLOW/REVIEW Did you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below. ⏰ TIMESTAMPS [00:00:00] Intro [00:01:54] VectorY: Raising the largest Series A in 2023 in 🇪🇺 [00:05:01] What's coming for ALS [00:07:50] How Vectorized Antibodies work [00:17:57] New Vector (AAV) technologies [00:22:55] The pipeline of VectorY [00:27:22] Where VC money is moving to [00:32:29] The Netherlands as a biotech cluster [00:35:31] CRISPR approval and gene therapy reimbursement [00:48:15] Where Sander came from [00:56:14] How to have the energy to be a serial entrepreneur

In an online special, we’re interviewing Thomas Clozal, the co-founder and CEO of Owkin. We talk about scaling AI in biotech and how it feels to be the child of billionaire biotech parents. 💎 ABOUT THE SPEAKER Thomas founded Owkin in 2016 and I first met him in 2017. At that time, Owkin was still a baby and I wasn’t sure where it would go. Now it’s a unicorn following a $180M investment from Sanofi in 2021 and has over 300 employees. 🔗 LINKS MENTIONED - Exscientia Expands Biologics Design Capability with Automated Laboratory https://investors.exscientia.ai/press-releases/press-release-details/2022/Exscientia-Expands-Biologics-Design-Capability-with-Automated-Laboratory/default.aspx - Marc de Garidel, Abivax | How to make two billion 💶 exits (kind of smoothly) | E09 https://youtu.be/njZR8udGBTQ - How AI Can Tackle Cancer - Leader in Innovation (Fast Company) https://open.spotify.com/episode/2LQGtAaD7ALSsHslNZJ1mC?si=96a0ba9ddafd4fbc - Aviv Regev leads Genentech's next revolution with AI - https://endpts.com/aviv-regev-leads-genentechs-next-revolution-with-ai/ 📜 TRANSCRIPT Read the full transcript here: https://flot.bio/episode/thomas-clozel-ai-biotech/ 🫶 FOLLOW US - Newsletter: http://eepurl.com/h_fnmH - LinkedIn: https://www.linkedin.com/company/flot-bio/ - X (Twitter): https://x.com/FlotBio 🎙️ ABOUT FLOT.BIO Flot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 10k monthly views. Free. ⭐️ SPONSORSHIP Ready to amplify your brand to influential leaders in biotech and biopharma? Contact nick@flot.bio and unlock sponsorship opportunities in our podcasts! 🙏 LIKE/FOLLOW/REVIEW Did you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below. ⏰ TIMESTAMPS [00:00:00] Intro [00:01:26] You need a good pipeline [00:09:24] How Owkin is scaling AI in biotech [00:16:46] Augmenting AI in biotech [00:23:05] How AI can work for small/medium biotech companies [00:27:18] Always looking for more data [00:33:58] Anonymization of data and federated learning [00:42:18] Becoming a biotech company [00:47:29] Small molecules [00:49:10] Limitations [00:51:51] Growing up with billionaire biotech parents [00:56:37] Becoming unfocused and having fun [01:09:02] Getting the best investors [01:18:51] Thanks for listening

Today, I’m in Paris (🇫🇷) to chat with Marc de Garidel, the new CEO of Abivax. We talk about the challenges behind the exits and why Abivax could be a third big success. 💎 ABOUT THE SPEAKER Marc is a biopharma veteran with an impressive track record. He has made two billion-dollar exits, was CEO of Ipsen, and has recently made the biggest French IPO ever with Abivax. 📜 TRANSCRIPT Read the full transcript here: https://flot.bio/episode/marc-de-garidel-abivax-exit/ 🫶 FOLLOW US Newsletter: http://eepurl.com/h_fnmH LinkedIn: https://www.linkedin.com/company/flot-bio/ X (Twitter): https://x.com/FlotBio 🎙️ABOUT FLOT.BIO Flot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 10k monthly views. Free. ⭐️ SPONSORSHIP Wanna reach 10,000+ biotech leaders at companies like BioNTech, Immunocore or Genmab? Feel free to message Nick (nick@flot.bio) to learn more. 🙏 LIKE/FOLLOW/REVIEW Did you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below. ⏰ TIMESTAMPS [00:00:00] Intro [00:01:32] Behind the scene of the 2 billion-dollar exits [00:20:48] Lessons on compliance analysis [00:24:09] What to do when the market is against you [00:36:08] Abivax: Phase II compared to standard of care [00:42:51] IBD and the microbiome [00:51:20] Why is 70% of the market in the US? [00:59:07] The best way to sell a company is to make a great product [01:03:48] Find people who inspire you [01:10:45] Thanks for listening 🙏

Today we're in Munich at BIO-Europe to chat with one of the best commentators in European biotech, Mike Ward. We talk about the best and the worst of the European biotech industry since the 80s. 💎 ABOUT THE SPEAKER Mike has been in biotech content since the birth of the industry in the 80s. He has worked at BioCentury, Informa/Scrip and now Clarivate. I’ve known Mike for many years and I like how clearly he sees things while being no-bullshit and fun. 📜 TRANSCRIPT Read the full transcript here: https://tinyurl.com/y428h2wr 🫶 FOLLOW US - Newsletter: http://eepurl.com/h_fnmH - LinkedIn: https://www.linkedin.com/company/flot-bio/ - X (Twitter): [https://x.com/FlotBio 🎙️ABOUT FLOT.BIO Flot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 10k monthly views. Free. ⭐️ SPONSORSHIP Ready to amplify your brand to influential leaders in biotech and biopharma? Contact nick@flot.bio and unlock sponsorship opportunities in our podcasts! 🙏 LIKE/FOLLOW/REVIEW Did you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below. ⏰ TIMESTAMPS [00:00:00] Intro [00:01:32] The best and worst of biotech [00:11:08] The beginnings of the EU biotech scene [00:21:38] It's all in cycles and echos [00:28:14] Biotech of today [00:45:12] Can biotechs make money? [00:56:31] Funding big vs small [01:16:15] The EU biotech world is very small [01:21:45] The changing media landscape [01:38:35] The rockstar of biotech [01:43:18] Thanks for listening

We’re live from Oslo 🇳🇴 to catch up with Agnete Fredriksen, co-founder and CBO of Nykode (ex-Vaccibody). In this episode, we chat about being one of the leading women in bio in Europe, the Nordics, and immunotherapies. 💎 ABOUT THE SPEAKER Agnete founded the immunotherapy company Nykode in 2006 which is now worth around $500M. For her PhD she designed and developed the first Vaccibody vaccine molecules, improving the outlook for cancer patients. I’ve known Agnete for many years and I like her sharpness while having this Scandinavian humility. 📜 TRANSCRIPT Read the full transcript here: https://tinyurl.com/yk364wes 🔗 FOLLOW US - Don't miss an episode by signing up for our monthly newsletter: http://eepurl.com/h_fnmH - LinkedIn: https://www.linkedin.com/company/flot-bio/ - X (Twitter) https://twitter.com/FlotBio 🎙️ ABOUT FLOT.BIO Our show is a unique addition to the European podcast scene, complementing other news-focused or locally-targeted podcasts. We bring you rare long-form conversations with the best in European biotech. Your host Philip animates the conversation to dig out exciting, and sometimes contrarian ideas. These might inspire you and help you grow. 10k monthly views. ⭐️ SPONSORSHIP Ready to amplify your brand to influential leaders in biotech and biopharma? Contact nick@flot.bio and unlock sponsorship opportunities in our podcasts! 🙏 LIKE/FOLLOW/REVIEW Did you enjoy the episode? Let us know your thoughts and what you found useful by dropping a comment. Also, make sure you like the episode and follow our channel so you never miss an episode and help others find it too. ⏰ TIMESTAMPS [00:00:00] Intro [00:00:52] Welcome [00:01:36] Women in biotech [00:25:35] Gender equality on the board [00:42:10] Raising $45 million [00:47:47] How the science works [01:01:20] Explaining the clinical results [01:07:19] The immunotherapy field [01:17:02] Biotech in Oslo [01:21:08] Thanks for listening

Biotech great Rodger Novak, Co-Founder and Chairman of CRISPR Tx joins us on the show. In this episode, we chat about bringing the first CRISPR drug to the market and why he thinks everything is wrong in bio in Europe besides science. Rodgers’ is a name everyone should know, having made it big in the global biotech scene. I first interviewed him back in 2016 at Labiotech. It’s a treat to be able to sit down with him again. 💎 ABOUT THE SPEAKER A serial entrepreneur, Rodger Novak has made it big through his many successful enterprises in the pharma and biotech scene. As co-founder of one of the hottest and best-known biotechs in the world, CRISPR Tx, he has been an instrumental player in bringing cutting-edge gene therapy to the world. Trained with a medical degree, he has also provided key contributions in the fields of anti-infectives, genetics and personalized medicine. 📜 TRANSCRIPT Read the full transcript here: https://tinyurl.com/9kucsnzt 🔗 LINKS MENTIONED: - Rodger at Hello Tomorrow 2022 - https://youtu.be/OWMRlLzJ5l8 - Rodger at Labiotech Refresh in 2019 - https://youtu.be/kp6m6BDckDk?si=RhjDeDi-n0crXMra - Rodger at Labiotech Refresh in 2016 - https://youtu.be/XFK-B1xJzGc?si=TG7ut5f-aGEgpLwg - Rodger on the Between Biotech Waves podcast - https://open.spotify.com/episode/1PFWLgJ80QmZwdN9Rmy6a7?si=0QLdSEJTSIe_et0vDarYmQ 🔗 FOLLOW US - Don't miss an episode by signing up for our monthly newsletter: http://eepurl.com/h_fnmH - LinkedIn: https://www.linkedin.com/company/flot-bio/ - X (Twitter): https://twitter.com/FlotBio 🎙️ ABOUT FLOT.BIO Our show is a unique addition to the European podcast scene, complementing other news-focused or locally-targeted podcasts. We bring you rare long-form conversations with the best in European biotech. Your host Philip animates the conversation to dig out exciting, and sometimes contrarian ideas. These might inspire you and help you grow. 10k monthly views. ⭐️ SPONSORSHIP Ready to amplify your brand to influential leaders in biotech and biopharma? Contact nick@flot.bio and unlock sponsorship opportunities in our podcasts! 🙏 LIKE/FOLLOW/REVIEW Did you enjoy the episode? Let us know your thoughts and what you found useful by dropping a comment. Also, make sure you like the episode and follow our channel so you never miss an episode and help others find it too. ⏰ TIMESTAMPS [00:00:00] Intro [00:00:38] Welcome [00:01:45] Bringing CRISPR to the market [00:17:33] Experience in biotech isn't everything [00:21:35] How important is CRISPR? [00:27:07] How to become best in class [00:33:40] The secret recipe for founding a successful company [00:37:28] Everything is wrong in biotech in Europe besides science [00:46:44] What can a young European founder do to bridge the US gap for biotech [00:57:01] The European attitude can get in the way of entrepreneurship [01:06:20] Follow Rodger Novak [01:09:23] Thanks for listening and follow Flot.bio

We’re back live and in Paris 🇫🇷 with our next guest, Johannes Fruehauf. We talk about reinventing the co-working labs for biotech startups, the difficulties of doing business in Europe, profitability in biotech, and much more (see timestamps below). 💎 ABOUT THE SPEAKER Johannes is the President, CEO, and founder of BioLabs, the biggest “incubator”, or as they like to call it “co-working laboratory”, platform for biotech startups in the world. Today they have over 14 locations, including 3 in Europe (2 in Paris and 1 in Heidelberg). He is also the founder of LabCentral and a general partner at Mission BioCapital. 📜 TRANSCRIPT Read the full transcript here: https://tinyurl.com/mt9dva8u 🔗 FOLLOW US - Don't miss an episode by signing up for our monthly newsletter: http://eepurl.com/h_fnmH - LinkedIn: https://www.linkedin.com/company/flot-bio/ - X (Twitter): https://twitter.com/FlotBio 🎙️ ABOUT FLOT.BIO Our show is a unique addition to the European podcast scene, complementing other news-focused or locally-targeted podcasts. We bring you rare long-form conversations with the best in European biotech. Your host Philip animates the conversation to dig out exciting, and sometimes contrarian ideas. Those might inspire you and help you grow. 10k monthly views. ⭐️ SPONSORSHIP Ready to amplify your brand to influential leaders in biotech and biopharma? Contact nick@flot.bio and unlock sponsorship opportunities in our podcasts! 🙏 LIKE/FOLLOW/REVIEW Did you enjoy the episode? Let us know your thoughts and what you found useful by dropping a comment. Also, make sure you like the episode and follow our channel so you never miss an episode and help others find it too. ⏰ TIMESTAMPS [00:00:00] Intro [00:00:39] Welcome to this new episode [00:02:19] How & why reinvent biotech incubators [00:14:14] The competitors [00:17:41] Entrepreneurship in Europe [00:22:11] The Challenges of doing business in Europe [00:29:37] People make it happen [00:36:51] BioLabs in Asia and Japan [00:41:46] Is a higher risk tolerance a good thing for everyone? [00:48:22] Money: being profitable in life sciences and not raising money if you don't have to. [00:59:15] Synergies between real estate and investing [01:14:01] Should you get a business coach? [01:25:52] Thanks for listening

In a virtual special, we welcome Bernat Olle to the show. We discuss the microbiome space, including Vedanta’s upcoming Phase 3, and how it feels to be a European founder in Boston. Bernat is the CEO and co-founder of Boston-based Vedanta Biosciences, one of the leading microbiome companies. They’ve had a positive Phase 2 trial and recently raised a $107M round to run a Phase 3. Bernat is a life science trailblazer. During his doctorate at MIT, he developed a novel method for large-scale bacterial culture. He's been named "Innovator of the Year in MIT Technology Review Spain's "Innovators under 35" awards and even has his own TED Talk! I’ve known Bernat since 2013 when I was studying in Boston and he was starting Vedanta. It was great to catch up again and become inspired once more. 📜 Read the full transcript here: https://tinyurl.com/yek8ctss 🔗 Links mentioned: Ep112: Bernat Olle on Microbiome Therapeutics - The Long Run with Like Timmerman - https://timmermanreport.com/2022/04/microbiome-based-drug-development-bernat-olle-on-the-long-run/ Ending the War on Microbes | Bernat Olle | TEDxCambridge : https://www.youtube.com/watch?v=yScP4Cm0-gE&pp=ygUQYmVybmF0IG9sbGUgdGVlZA%3D%3D 🔗 FOLLOW US - Don't miss an episode by signing up for our monthly newsletter: http://eepurl.com/h_fnmH - LinkedIn: https://www.linkedin.com/company/flot-bio/ - X (Twitter): https://twitter.com/FlotBio 🎙️ ABOUT FLOT.BIO Our show is a unique addition to the European podcast scene, complementing other news-focused or locally-targeted podcasts. We bring you rare long-form conversations with the best in European biotech. Your host Philip animates the conversation to dig out exciting, and sometimes contrarian ideas. Those might inspire you and help you grow. 10k monthly views. ⭐️ SPONSORSHIP Ready to amplify your brand to influential leaders in biotech and biopharma? Contact nick@flot.bio and unlock sponsorship opportunities in our podcasts! 🙏 LIKE/FOLLOW/REVIEW Did you enjoy the episode? Let us know your thoughts and what you found useful by dropping a comment. Also, make sure you like the episode and follow our channel so you never miss an episode and help others to find it too. ⏰ Timestamps: (00:00:00) Intro (00:00:56) Welcome (00:02:36) Zooming out on the microbiome field (00:11:44) Standardizing the process and composition (00:21:39) What's the cost? (00:27:16) Scalability (00:33:05) The many microbiome companies (00:39:43) EU microbiome industry (00:43:51) Challenge of fundraising (00:49:23) Running a company in the US vs EU (01:00:30) Would you recommend the entrepreneurial path? (01:06:04) What can I do for my microbiome? (01:18:06) Follow Bernat (01:19:09) Wrapping up

It’s a treat to welcome Ingmar Hoerr on the show. We chat about building a 20B dollar biotech startup, almost dying on the job, and why people skills are so important in biotech. Ingmar is a pioneer in the EU biotech scene, revolutionizing drug development with mRNA therapeutics. He and his team created the initial technology used in mRNA vaccines and submitted the first patents for its use. CureVac helped other mRNA companies such as Moderna and BioNTech successfully solve the Covid pandemic. Ingmar is very inspiring, as he is visionary and bold while remaining humble and caring. I’ve known him for almost a decade and each interaction with him was memorable. This long episode, and the lunch that followed, is yet another example. Enjoy 😉 📜 Read the full transcript here: https://tinyurl.com/5n7d3652 🔗 FOLLOW US - Don't miss an episode by signing up for our monthly newsletter: http://eepurl.com/h_fnmH - LinkedIn: https://www.linkedin.com/company/flot-bio/ - X (Twitter): https://twitter.com/FlotBio 🎙️ ABOUT FLOT.BIO Our show is a unique addition to the European podcast scene, complementing other news-focused or locally-targeted podcasts. We bring you rare long-form conversations with the best in European biotech. Your host Philip animates the conversation to dig out exciting, and sometimes contrarian ideas. Those might inspire you and help you grow. 10k monthly views. ⭐️ SPONSORSHIP Ready to amplify your brand to influential leaders in biotech and biopharma? Contact nick@flot.bio and unlock sponsorship opportunities in our podcasts! 🙏 LIKE/FOLLOW/REVIEW Did you enjoy the episode? Let us know your thoughts and what you found useful by dropping a comment. Also, make sure you like the episode and follow our channel so you never miss an episode and help others to find it too. ⏰ Timestamps: (00:00:00) Intro (00:00:53) Welcome (00:01:54) Background (00:05:53) The mindset to make change (00:06:59) Early days of RNA and mice (00:08:55) The beginnings of CureVac (00:13:39) How to survive while founding a company (00:15:03) Where did the money come from? (00:19:19) The key to getting the funds (00:20:22) Getting the lab running (00:22:34) Advancing RNA for humans (00:24:29) Becoming a real biotech company (00:27:31) Surviving the startup phase (00:28:54) Investing in vision (00:33:06) Getting proof of concept (00:35:15) Phase one (00:37:35) Phase two - failure is important (00:42:51) Pharma partnerships (00:47:01) Flu, rabies, and covid (00:49:33) Stepping down to add in USA spirit (00:53:01) Close to death (00:57:49) Coming to peace with a new role (01:02:06) The pandemic (01:08:35) RNA people (01:10:51) Moving on from CureVac (01:11:53) Creating a foundation (01:16:48) Freedom (01:27:46) Biotech people are risk takers (01:29:29) Sharing inspiration (01:37:28) Reflection is key (01:40:42) Making decisions (01:51:37) People are important (02:05:39) Strengths vs weakness (02:11:32) Creating a common culture (02:29:11) Thanks for listening

It's great to have Werner Lanthaler, the CEO of Evotec, one of the largest biotech research companies in Europe/the world, on the show. We have known each other for almost ten years now. He's not only sharp but also friendly and easy to talk to. In this episode, we chat about leading AI in biotech, the sharing economy in the industry, how to be authentic, and more. Hope it helps you learn, be inspired and grow 😉 📜 Read the transcript here: https://tinyurl.com/p62vxwty 🔗 FOLLOW US - Don't miss an episode by signing up for our monthly newsletter: http://eepurl.com/h_fnmH - LinkedIn: https://www.linkedin.com/company/flot-bio/ - X (Twitter): https://twitter.com/FlotBio 🎙️ ABOUT FLOT.BIO Our show is a unique addition to the European podcast scene, complementing other news-focused or locally-targeted podcasts. We bring you rare long-form conversations with the best in European biotech. Your host Philip animates the conversation to dig out exciting, and sometimes contrarian ideas. Those might inspire you and help you grow. 10k monthly views. ⭐️ SPONSORSHIP Ready to amplify your brand to influential leaders in biotech and biopharma? Contact nick@flot.bio and unlock sponsorship opportunities in our podcasts! 🙏 LIKE/FOLLOW/REVIEW Did you enjoy the episode? Let us know your thoughts and what you found useful by dropping a comment. Also, make sure you like the episode and follow our channel so you never miss an episode and help others to find it too. ⏰Timestamps: (00:00:00) Intro (00:00:37) Welcome (00:02:49) AI in biotech (00:10:08) What AI means for staff (00:11:27) How are biotech companies using AI today? (00:15:28) Biotech - a sharing industry (00:25:32) Trending back to integrated companies (00:30:46) The global EU biotech industry (00:36:03) A brighter funding future (00:44:01) Background on Werner (00:48:12) From no science to CEO (00:59:04) Staying humble (01:04:06) Mindmaps for motivation (01:09:27) A typical day (01:12:33) What's Evotec building? (01:18:32) Follow Werner and Evotec (01:19:42) Thanks for listening (01:20:20) About Flot.bio

For our first episode, we catch up with Antoine Papiernik, the chairman of Sofinnova partners, one of the top EU biotech VC funds. We chat about building billion-euro biotechs in Europe, being listed on the Midas list (without letting it go to your head), the importance of being good at selling, being lucky, and how to balance all this with family priorities. I've been lucky to know and be inspired by Antoine for almost 10 years. Over his successful career, he has invested in over 500 companies, focusing on platform companies and entrepreneurs. He currently has over €2.5 billion under management in several funds, both early and late, in drug development, industrial biotech, and medtech. Antoine is a remarkable speaker and a good fun person. 📜 Read the full transcript here: https://tinyurl.com/57fn8b49 🔗 FOLLOW US - Don't miss an episode by signing up for our monthly newsletter: http://eepurl.com/h_fnmH - LinkedIn: https://www.linkedin.com/company/flot-bio/ - X (Twitter): https://twitter.com/FlotBio 🎙️ ABOUT FLOT.BIO Our show is a unique addition to the European podcast scene, complementing other news-focused or locally-targeted podcasts. We bring you rare long-form conversations with the best in European biotech. Your host Philip animates the conversation to dig out exciting, and sometimes contrarian ideas. Those might inspire you and help you grow. 10k monthly views. ⭐️ SPONSORSHIP Ready to amplify your brand to influential leaders in biotech and biopharma? Contact nick@flot.bio and unlock sponsorship opportunities in our podcasts! 🙏 LIKE/FOLLOW/REVIEW Did you enjoy the episode? Let us know your thoughts and what you found useful by dropping a comment. Also, make sure you like the episode and follow our channel so you never miss an episode and help others to find it too. ⏰ Timestamps: (00:00) Intro (00:27) Welcome (02:17) Background and serendipity (05:25) Getting into investment (07:23) I wouldn't hire me (09:23) Are you lucky and curious? (14:27) Joining Sofinnova (17:38) Becoming Managing Partner (19:10) Midas List (20:41) You're only as good as your last deal (21:45) Equal opportunity (28:03) How to get funded (31:12) Europe vs USA( 35:54) How Europe can do better (39:27) Crossing the chasm to the future (41:04) Follow Antoine (41:35) Wrapping up